Biomedicines presents promising results from phase II trials of omega interferon for the treatment of hepatitis C

November 12, 2001

Dallas, Texas, November 12, 2001 - BioMedicines, Inc. today announced positive results from two Phase II clinical trials employing the company's omega interferon for the treatment of patients chronically infected with the hepatitis C virus (HCV). The results from clinical trials conducted at the Scripps Institute in the United States, as well as interim findings from a larger European multicenter clinical trial, were presented at the 52nd annual American Association for the Study of Liver Disease (AASLD) conference in Dallas on November 11, 2001.

"Omega interferon is a natural human interferon produced by genetic engineering technologies," said BioMedicines' Chief Medical Officer, Dr. Peter Langecker, "Results from these two independent studies provide evidence for an antiviral effect against all HCV genotypes (1, 2, 3, and 4). Despite occasional symptoms typically associated with interferon treatment, patients appeared to tolerate omega interferon quite well. As a result, we were able to continue raising the dose level, producing progressive anti-hepatitis C effects."

The European study was undertaken to evaluate the safety, tolerability and antiviral activity of six different dose levels of omega interferon in previously untreated patients with chronic hepatitis C. In this open-label study patients were treated for 3-12 months. All major HCV genotypes were present. Antiviral activity was assessed by measuring blood levels of HCV RNA and by liver enzyme testing. The interim results show that omega interferon can reduce HCV to undetectable levels in interferon-naïve patients having any of the four major HCV genotypes.

The U.S. study was designed to evaluate the effect of increasing dose levels of omega interferon in three groups of patients with genotype 1, hepatitis C infection that was completely resistant to prior treatment with alpha interferon given with or without a second antiviral drug. Resistance meant that HCV was always detectable in blood despite treatment with alpha interferon. Within 48 hours of the initiation of treatment with omega interferon, HCV RNA fell sharply in all patients, and in some to undetectable levels.

Chief Executive Officer Dr. Mark Moran said, "We are pleased with these results. We believe they also support our new drug delivery efforts with this drug. In collaboration with ALZA, we are also putting omega interferon into the implantable DUROS® delivery system. With DUROS®, we hope to be able to deliver omega interferon for months with a single administration.

Hepatitis C infection can lead to severe impairment of liver function, liver fibrosis, and liver cancer. According to the U.S. Center for Disease Control, HCV infects nearly 3 million people in the United States, and the World Health Organization estimates 170 million people are infected worldwide. Many infected persons are unaware of the infection. The spread of HCV infection has reached epidemic proportions, as some experts believe that without substantial improvements in treatment, the death toll from HCV infection will surpass that from HIV.
-end-
About BioMedicines, Inc.

BioMedicines, Inc., a privately held pharmaceutical company, is developing first line therapies for the treatment of cancer and infectious diseases such as viral hepatitis. The company specializes in redirecting the development of drugs to new and more valuable indications. The company has current development and/or commercialization agreements with ALZA Corporation, Boehringer Ingelheim International GmbH, Schering AG, and G.D. Searle & Co. Additional information about BioMedicines, Inc. can be found on the World Wide Web at www.biomedicinesinc.com.

Noonan/Russo Communications

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.